SANTA CLARA – Practicing behind a patchwork line is not how Brock Purdy dreamed of spending his 25th birthday Friday, never mind that he just gifted 49ers linemen a caravan of trucks and sports-utility vehicles on two-year leases. The 49ers are poised to field their most inexperienced offensive line in at least coach Kyle Shanahan’s eight seasons. Monday night’s chore for whoever blocks: protect Purdy and clear lanes for ball carriers Isaac Guerendo and Deebo Samuel against the NFC-leading Detroit Lions at Levi’s Stadium. Injuries have so thoroughly depleted the Niners (6-9) that 3-of-5 spots could feature linemen making their 49ers’ starting debuts. The only healthy starters are center Jake Brendel and right guard Dominick Puni, who might have to shift to other spots to provide for the best five-man look. Left tackle Trent Williams and his backup, Jaylon More, both went this week on injured reserve, which is where left guard Aaron Banks is expected to land before Monday night’s 5:15 p.m. kickoff. Right tackle Colton McKivitz did not practice Thursday, after being limited by a knee issue, and versatile backup Spencer Burford has been out with a calf injury he sustained as the sub at left tackle in Sunday’s loss at Miami. Offensive linemen Ben Bartch and Jon Feliciano are on injured reserve. Nick Zakelj is expected to make the first start of his career, most likely at left guard. “I know it’s just an amazing opportunity to have,” Zakelj said. “I can’t wait to go grasp it and go out there, fly off the ball and let it loose.” Charlie Heck, poached Wednesday off the Arizona Cardinals’ practice squad, made 21 career starts for the Houston Texans from 2020-23, and Thursday acquisition Matt Hennessy made 22 starts as the Atlanta Falcons’ 2020-22 center. No other linemen have starting experience, including Zakelj, Austen Pleasants, Sebastian Gutierrez, Isaac Alarcon and undrafted rookie center Drake Nugent. If McKivitz is healthy, he’s an option to move to left tackle, where he made spot starts at left tackle in 2021 and ’22 in place of Williams. Burford, unbeknownst until last game, had practiced as the No. 3 left tackle most of the season. LYNCH’S STATE OF FRANCHISE General manager John Lynch, speaking for the first time since Sunday’s official elimination from the playoffs, is in the investigation process of examining the 49ers’ 2024 woes and potential cures. “I can’t believe we’re here, but we are. We have to accept that. We have to learn from that,” Lynch said on KNBR 680-AM. “We can’t just chalk it up to, ‘There were a lot of injuries.’ The team we’re playing, Detroit, they had a lot of injuries but they found a way. We have to look at the root, and we have been looking at the root causes. We’ll fix it.” One obvious issue is the 49ers’ inability to close out games, something that’s carried over from past playoff defeats to this season’s four NFC West defeats. Lynch noted that the absences of All-Pros Williams and Christian McCaffrey factors into that. “But we can’t chalk it up to just that. We have to go deeper,” Lynch said. “There are ways we could have gotten it done. When you have division opponents (down) multiple scores, you have to put people away, and that’s what we didn’t do this year. We have to own that. We have to get to the bottom of why exactly that happened, with every decision we make.” HEALTH CENTER Fullback Kyle Juszczyk did not practice because of illness. Juszczyk has played every game this season after taking a pay cut in the spring. He is aiming for his ninth straight Pro Bowl invitation. Running back Isaac Guerendo participated in a second straight practice and looks on track to make his third career start; he did not play in Sunday’s loss at Miami because of hamstring and foot injuries. Running back David Montgomery (knee) was the only player on the Lions’ active roster not to practice. Cornerback Terrion Arnold (illness) was limited after missing Thursday’s session. Full participants were guard Graham Glasgow (knee), wide receiver Kalif Raymond (foot) and linebacker Jalen Reeves-Maybin (neck). GAMEDAY GUIDE Levi’s Stadium parking lots are to open at 1:45 p.m. Stadium gates open 30 minutes later for club- and suite-ticket holders, with entry for all others starting at 3:15 p.m. Halftime entertainment will feature MIMS and Freedom Williams (from the C+C Music Factory). Tony Lindsay will perform the national anthem.NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global urea cycle disorder treatment market size is estimated to grow by USD 215.4 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 3.2% during the forecast period. Increasing prevalence of urea cycle disorder is driving market growth, with a trend towards increasing growth potential in emerging economies. However, low access to specialized care poses a challenge. Key market players include Abbott Laboratories, Acer Therapeutics Inc., Aeglea BioTherapeutics Inc., Arcturus Therapeutics Holdings Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, CAMP4, Dipharma SA, Eurocept B.V., Horizon Therapeutics Plc, Immedica Pharma AB, Medunik USA , Nestle SA, Orpharma Pty Ltd., Reckitt Benckiser Group Plc, Recordati S.p.A, RELIEF THERAPEUTICS Holding SA, Swedish Orphan Biovitrum AB, Synlogic Inc., and Ultragenyx Pharmaceutical Inc.. Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Market Driver The Urea Cycle Disorder (UCD) treatment market is experiencing significant growth due to increasing demand for advanced screening and diagnosis of diseases, rising healthcare expenditure, and the expansion of the healthcare industry in developing economies like India and China . These countries offer substantial market opportunities with large untapped potential for UCD product manufacturers. The healthcare sector in these regions is growing rapidly, driven by demographic shifts and rising healthcare expenditure. The number of hospitals in developing countries is increasing, leading to a higher demand for advanced diagnostic procedures. For instance, India and China had over 69,264 hospitals combined in 2020. This trend is expected to continue, increasing the demand for medical instruments, including those used in UCD treatment. The relatively low labor costs and abundance of raw material suppliers in these countries also attract vendors to establish a presence, making it an attractive market for both established players and new entrants. The Urea Cycle Disorders (UCDs) market is experiencing significant growth, driven by the increasing prevalence of these metabolic disorders and the development of new treatments. According to a recent market report by Statpearls, key players in the market include Acer Therapeutics Inc, Thoeris GmbH, and Boehringer Ingelheim. Their offerings include Carglumic acid, OLPRUVA (sodium phenylbutyrate), and amino acid supplements like glycerol phenylbutyrate and sodium benzoate. The COVID-19 outbreak in Wuhan, China , has impacted the market, leading to disruptions in R&D spending in the pharmaceutical sector. However, the demand for oral and injectable treatments for UCDs, such as OTC Ornithine Transcarbamylase and AS Argininosuccinate Synthetase, remains strong. New treatments like CARBAGLU and RAVICTI are gaining popularity due to their effectiveness in managing conditions like hepatomegaly and hyperammonemia. The market is expected to continue growing, with biotech companies and research institutes in EU member states investing heavily in the development of new treatments for enzyme deficiency types of UCDs. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges Urea Cycle Disorders (UCDs) necessitate specialized treatment from experienced healthcare providers due to their complex nature. However, access to such care is limited, particularly in remote and underserved regions. The scarcity of expert healthcare providers and geographic barriers result in a low number of diagnosed cases and suboptimal treatment. UCD care involves multidisciplinary approaches, including dietary modifications, medications, and ammonia level monitoring. These complexities lead to delayed diagnoses, inadequate treatment, and minimal support for patients and their families. These challenges hinder the growth of the UCD treatment market during the forecast period. The Urea Cycle Disorders (UCDs) market faces challenges due to the complexities of treating these conditions. Key players like Acer Therapeutics Inc. Offer solutions with their products, such as Carglumic acid for hepatic UCDs and OLPRUVA (sodium phenylbutyrate) for UCDs with hyperammonemia. The COVID-19 outbreak in Wuhan, China , disrupted supply chains, affecting the market. Amino acid supplements, including glycerol phenylbutyrate and sodium benzoate, are also used. OTC ornithine transcarbamylase and AS argininosuccinate synthetase are available, but their efficacy varies. Market reports indicate a growing demand for oral and injectable treatments in hospital, retail, and online pharmacies. Companies like Thoeris GmbH, Boehringer Ingelheim, and Acer Therapeutics are investing in R&D to address enzyme deficiency types like ornithine transcarbamylase deficiency. The pharmaceutical sector and biotech companies, along with research institutes in EU member states, are collaborating to advance treatments. The route of administration and managing hepatomegality are crucial considerations. Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This urea cycle disorder treatment market report extensively covers market segmentation by 1.1 Glycerol phenylbutyrate 1.2 Sodium phenylbutyrate 1.3 Amino acid supplements 1.4 Sodium benzoate 1.5 Others 2.1 Oral 2.2 Injectables 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) 1.1 Glycerol phenylbutyrate- Urea cycle disorders (UCDs) are metabolic conditions that affect the normal processing of ammonia in the body. Treatment for UCDs involves managing diet and medication. Nutritional therapy focuses on restricting protein intake and providing specialized formulas. Medications like sodium phenylbutyrate and glycine help convert ammonia to urea for elimination. Regular monitoring of blood ammonia levels is crucial for effective treatment. Pharmaceutical companies develop and market these essential medications, ensuring patients receive proper care and management for UCDs. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis The Urea Cycle Disorder (UCD) treatment market encompasses a range of protein-based therapies and amino acid supplements used to manage these rare metabolic disorders. UCDs, including ornithine transcarbamylase deficiency and hyperammonemia, impair the body's ability to process ammonia, leading to toxic buildup. R&D spending in the pharmaceutical sector and biotech companies, as well as research institutes in EU member states, is driving innovation in UCD treatments. Amino acid supplements, such as glycerol phenylbutyrate and sodium benzoate, are commonly used to provide alternative sources of nitrogen for the urea cycle. OTC ornithine transcarbamylase and argininosuccinate synthetase enzyme replacements are also available. These treatments are administered through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. Key therapies include oral and injectable forms of these supplements and enzyme replacements. Statpearls, a leading provider of medical information, reports ongoing research and development in this field. Acer Therapeutics Inc is one of the notable players focusing on UCD treatments, with a pipeline of potential therapies. Market Research Overview Urea Cycle Disorders (UCDs) are rare metabolic conditions caused by enzyme deficiencies, leading to an accumulation of ammonia in the blood. Protein breakdown in the body results in the formation of ammonia, which is normally converted into urea for elimination. However, in UCDs, this process is disrupted, leading to hyperammonemia and potential neurological damage. The pharmaceutical sector and biotech companies, including research institutes in EU member states, are investing significantly in R&D for UCD treatments. Ornithine transcarbamylase deficiency (OTCD) is a common UCD, and treatments include sodium phenylbutyrate (Thoeris GmbH, OLPRUVA) and glycerol phenylbutyrate. Other treatments include Carglumic acid, sodium benzoate, and amino acid supplements. The market for UCD treatments is growing, with oral and injectable medications available through hospital pharmacies, retail pharmacies, and online pharmacies. Companies like Boehringer Ingelheim, Acer Therapeutics, and Statpearls are developing new treatments for UCDs, including RAVICTI and CARBAGLU. The COVID-19 outbreak in Wuhan, China , has disrupted supply chains for some UCD treatments, leading to shortages in certain regions. UCDs are complex conditions that require ongoing management and monitoring, including regular blood tests for ammonia levels. Treatment may also involve dietary modifications and lifestyle changes. The market for UCD treatments is expected to continue growing as new treatments are developed and approved. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Therapy Glycerol Phenylbutyrate Sodium Phenylbutyrate Amino Acid Supplements Sodium Benzoate Others Route Of Administration Oral Injectables Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE Technavio
234win 8888
。
dished out advice for recreating his "trivela" assist on FIFA after starring in 's 5-1 win against in LaLiga on Tuesday. The 17-year-old returned to the starting lineup for the first time since Nov. 3 after recovering from an ankle injury as Barça ended a three game winless run in the league. He won the penalty which led to Barça's second goal and then set up for the third with a sublime pass with the outside of his boot, which he pointed out can be easily recreated on PlayStation. "I think the button on FIFA is L2 [for the trivela pass]," he told Esport3 after the match. "It is something I can do quite well, something I usually do and something I will keep doing." It's the second time this season that Yamal, who has a league-high eight assists, has teed up Raphinha with the outside of his boot. He played a similar pass, albeit from a much longer distance, in the win over earlier in the campaign. "I am really happy for Raphinha, we have a good understanding," Yamal added. "And he knows when I am in that area of the pitch, I will always try that pass." ' opener was cancelled out by Mallorca's before the break, but Barça pulled clear in the second half courtesy of a brace from Raphinha, his 15th and 16th goals of the season, and strikes from substitutes Frankie de Jong and . De Jong's goal, set up by Victor, also came after Yamal had played another pass in behind the Mallorca defence with the outside of his boot. The win moved Barça four points clear at the top of LaLiga, although second-placed have two games in hand, starting with on Wednesday. "It was a really important win after two defeats [in three games] in LaLiga," Yamal said. "So it was important to win with a result like this. We are really happy. "We have been good in the Champions League, but in LaLiga we were dropping silly points. This was a big win for everyone. The goals for those that play less will give them a lot of confidence." Barça have now won all 12 league games that Yamal has started this season. They have failed to win any of the four when he has not been in the starting lineup -- losing three and drawing one. "Lamine is always important," coach Hansi Flick said of the teenager's return to fitness. "With his quality, he is a huge difference in our team. He also could score today one or two goals." Flick, who rested striker against Mallorca, also joked he is happy to see the back of November after defeats to and and a draw against . "Today was really important to win this match," he added. "We deserve this win, these three points. We created chances, scored [them] and it was really fantastic. "We are happy. We are happy that s--t November is over and now we start with December."WASHINGTON (AP) — Carmelo Pacheco's 18 points helped Mount St. Mary's defeat Howard 79-75 on Saturday. Pacheco shot 6 for 8 from beyond the arc for the Mountaineers (5-2). Dallas Hobbs shot 5 of 16 from the field, including 1 for 8 from 3-point range, and went 6 for 7 from the line to add 17 points. Terrell Ard Jr. had 16 points and shot 4 of 6 from the field and 8 of 8 from the free-throw line. Anwar Gill finished with 18 points for the Bison (3-5). Blake Harper added 15 points, seven rebounds and two steals for Howard. Joshua Strong also had 12 points. ___ The Associated Press created this story using technology provided by and data from . The Associated PressConcerns raised over hospitality staff after smoking curbs ditched
Patrick Fishburn leads at Sea Island as Joel Dahmen keeps alive hopes of keeping his job
BETHLEHEM – William “Bill” Franklin Stinson Sr., 86, of Bethlehem, passed peacefully into the gates of Heaven on Sunday, Dec. 1, 2024, at Waterbury Hospital. He was the devoted and loving husband of Patricia Ann (Calabrese) Stinson, with whom he shared 63 years of marriage, having married on May 27, 1961. Bill was born on July 17, 1938, in Coco Solo, Panama Canal Zone, to the late Benjamin Allen Stinson and Helen Louise (Boone) Stinson. Bill was predeceased by his sister Ethel Mae Norfleet. Bill’s life was defined by an unwavering dedication to service – to his country, his family, and to all fortunate enough to know him. In 1958, he enlisted in the United States Air Force, and proudly served his country for more than 25 years, rising to the rank of lieutenant colonel. During his distinguished career, Bill worked as an electrical engineer and program manager, playing a key role in the development of the Airborne Warning and Control System (AWACS). His military service also included deployment to Korea, and mastery of the Chinese language through the Yale Institute of Asian Studies, demonstrating his commitment to broadening his understanding of the world. After retiring from the Air Force, Bill continued his professional journey at General DataComm, where he served as program manager for more than 15 years. Later, in continued dedication of service to others, he shared his knowledge and expertise with the students at The Gunnery in Washington, Conn., where he worked as a computer teacher and IT technician until his retirement in 2008. In addition to his professional accomplishments, Bill had a passion for sports and intellectual pursuits. He enjoyed playing tennis and golf, building computers from scratch, completing crossword puzzles, and keeping up with the latest technological innovations. Bill’s legacy will live on through his beloved wife, Patricia, and their three children: William “Bill” F. Stinson Jr. and his wife Susan, of Frisco, Texas; Rebecca “Becky” Stinson of Middlebury; and Benjamin “Ben” Allen Stinson and his wife, Patricia, of Roxbury. He is also survived by his three grandsons and one great-grandson, Tyler Stinson, Logan Stinson and his wife Sofia, and Hunter Stinson and his wife Samantha, and son Archer; as well as many nieces, nephews, and extended family members who will cherish his memory. Bill was a man of integrity, compassion, and wisdom who selflessly put the needs of others before his own. Despite his many accomplishments, Bill was humble and despite any hardship he endured, relentlessly strove to make this world a better place for all in it. Although it was in his nature to avoid superlatives, to all who knew him, he was the best husband, brother, father, and grandfather anyone could ever ask for. The memory of Mr. Fantastic will live on in the hearts of those who were fortunate enough to be part of his life. A funeral will be on Friday, Dec. 6, 2024, 8:45 a.m. at Chase Parkway Memorial/The Albini Family Funeral Home, 430 Chase Parkway, Waterbury, to St. John the Evangelist Church, Watertown, for a Mass of Christian Burial at 10 a.m. Burial with full military honors will follow at Lake Elise Cemetery in Middlebury. Calling hours for Bill will be Thursday evening from 5 to 7 p.m. at Chase Parkway Memorial. In lieu of flowers, memorial contributions can be made in Bill’s memory to: Tunnels to Towers Foundation (t2t.org/donate), 2361 Hylan Blvd., Staten Island, NY 10306. For information or to send e-condolences, visit chaseparkwaymemorial.com.NEW YORK — U.S. stocks tiptoed to more records amid a mixed Tuesday of trading, tacking a touch more onto what’s already been a stellar year so far. The S&P 500 edged up by 2 points, or less than 0.1%, to set an all-time high for the 55th time this year. It’s climbed in 10 of the last 11 days and is on track for one of its best years since the turn of the millennium. The Dow Jones Industrial Average slipped 76 points, or 0.2%, while the Nasdaq composite added 0.4% to its own record set a day earlier. AT&T rose 4.6% after it boosted its profit forecast for the year. It also announced a $10 billion plan to send cash to its investors by buying back its own stock, while saying it expects to authorize another $10 billion of repurchases in 2027. On the losing end of Wall Street was U.S. Steel, which fell 8%. President-elect Donald Trump reiterated on social media that he would not let Japan’s Nippon Steel take over the iconic Pennsylvania steelmaker. Nippon Steel announced plans last December to buy the Pittsburgh-based steel producer for $14.1 billion in cash, raising concerns about what the transaction could mean for unionized workers, supply chains and U.S. national security. Earlier this year, President Joe Biden also came out against the acquisition. Tesla sank 1.6% after a judge in Delaware reaffirmed a previous ruling that the electric car maker must revoke Elon Musk’s multibillion-dollar pay package. The judge denied a request by attorneys for Musk and Tesla’s corporate directors to vacate her ruling earlier this year requiring the company to rescind the unprecedented pay package. All told, the S&P 500 rose 2.73 points to 6,049.88. The Dow fell 76.47 to 44,705.53, and the Nasdaq composite gained 76.96 to 19,480.91. In the bond market, Treasury yields held relatively steady after a report showed U.S. employers were advertising slightly more job openings at the end of October than a month earlier. Continued strength there would raise optimism that the economy could remain out of a recession that many investors had earlier worried was inevitable. The yield on the 10-year Treasury rose to 4.23% from 4.20% from late Monday. Yields have seesawed since Election Day amid worries that Trump’s preferences for lower tax rates and bigger tariffs could spur higher inflation along with economic growth. But traders are still confident the Federal Reserve will cut its main interest rate again at its next meeting in two weeks. They’re betting on a nearly three-in-four chance of that, according to data from CME Group. Lower rates can give the economy more juice, but they can also give inflation more fuel. The key report this week that could guide the Fed’s next move will arrive on Friday. It’s the monthly jobs report, which will show how many workers U.S. employers hired and fired during November. It could be difficult to parse given how much storms and strikes distorted figures in October. Based on trading in the options market, Friday’s jobs report appears to be the biggest potential market mover until the Fed announces its next decision on interest rates Dec. 18, according to strategists at Barclays Capital. In financial markets abroad, the value of South Korea’s currency fell 1.1% against the U.S. dollar following a frenetic night where President Yoon Suk Yeol declared martial law and then later said he’d lift it after lawmakers voted to reject military rule. Stocks of Korean companies that trade in the United States also fell, including a 1.6% drop for SK Telecom. Japan’s Nikkei 225 jumped 1.9% to help lead global markets. Some analysts think Japanese stocks could end up benefiting from Trump’s threats to raise tariffs, including for goods coming from China. Trade relations between the U.S. and China took another step backward after China said it is banning exports to the U.S. of gallium, germanium, antimony and other key high-tech materials with potential military applications. The counterpunch came swiftly after the U.S. Commerce Department expanded the list of Chinese technology companies subject to export controls to include many that make equipment used to make computer chips, chipmaking tools and software. The 140 companies newly included in the so-called “entity list” are nearly all based in China. In China, stock indexes rose 1% in Hong Kong and 0.4% in Shanghai amid unconfirmed reports that Chinese leaders would meet next week to discuss planning for the coming year. Investors are hoping it may bring fresh stimulus to help spur growth in the world’s second-largest economy. In France, the CAC 40 rose 0.3% amid continued worries about politics in Paris, where the government is battling over the budget.